Cannabis has several well-studied medical benefits, particularly for chronic pain, nausea from chemotherapy, and muscle spasticity. It also shows promise for appetite stimulation and certain digestive conditions. Some benefits are backed by strong clinical evidence, while others are more limited or come with significant trade-offs. Here’s what the research actually supports.
Chronic Pain Relief
Pain management is the most common reason people use medical cannabis, and it’s the benefit with the broadest evidence behind it. For neuropathic pain (the burning, shooting kind caused by nerve damage), patients taking a THC/CBD combination were about 1.75 times more likely to achieve a 30% reduction in pain compared to placebo. They were also 1.4 times more likely to hit the higher bar of 50% pain reduction, though that result was less statistically reliable.
These numbers matter because neuropathic pain is notoriously difficult to treat. Standard medications like certain antidepressants and anti-seizure drugs work for some people but leave many with inadequate relief. Cannabis appears to offer a meaningful additional option, particularly for people who haven’t responded well to conventional treatments. The effect isn’t dramatic for everyone, but for a condition where even modest improvement changes daily functioning, a 30% pain reduction can be the difference between being housebound and getting through a workday.
Nausea From Chemotherapy
One of the oldest recognized medical uses of cannabis is controlling the severe nausea and vomiting that chemotherapy causes. A phase II/III clinical trial tested an oral THC/CBD formulation (equal parts of each) in cancer patients whose nausea persisted despite standard anti-nausea medications. Adding THC/CBD tripled the rate of complete response, from 8% with placebo to 24% with treatment.
That 24% number might sound modest, but context matters. These were patients who had already failed standard anti-nausea drug combinations, often three medications at once. For people in that situation, even partial relief can make the difference between tolerating another round of chemotherapy and stopping treatment. Researchers have noted that head-to-head comparisons with other rescue medications are still needed, so cannabis isn’t necessarily the best option in this space, but it’s a legitimate one.
Muscle Spasticity in Multiple Sclerosis
For people with multiple sclerosis, involuntary muscle tightness and spasms can be one of the most disabling daily symptoms. A pharmaceutical-grade cannabis spray (containing both THC and CBD) has been specifically studied for this. In clinical use, it reduced spasticity severity in the majority of patients treated, with about 73% achieving a clinically important improvement of 30% or more on a standard rating scale.
This benefit is well-established enough that the spray is an approved medication for MS-related spasticity in several countries. It represents one of the clearest examples of cannabis compounds being refined into a predictable, doseable treatment rather than relying on smoking or edibles with variable potency.
Appetite Stimulation
The “munchies” aren’t just a stereotype. Cannabis reliably increases appetite, and this effect has genuine medical value for people dealing with severe weight loss from conditions like HIV or cancer. THC activates receptors in the brain that regulate hunger signals, making food more appealing and increasing the amount people eat in a sitting.
A synthetic version of THC has been approved for years specifically to treat appetite loss and wasting in these populations. For someone who has lost dangerous amounts of weight due to illness, the ability to eat more consistently can be a critical part of recovery and maintaining enough strength to tolerate other treatments.
Digestive Conditions Like Crohn’s Disease
Cannabis shows intriguing results for inflammatory bowel conditions, particularly Crohn’s disease. In a controlled study, 90% of Crohn’s patients using cannabis had a meaningful clinical response (a drop of more than 100 points on the standard disease activity scale), compared to 40% on placebo. Even more striking, 45% of the cannabis group achieved full remission, versus 10% on placebo.
The caveat here is study size. This trial included only 21 patients, so while the results are encouraging, they’re far from conclusive. The improvements patients reported were real and significant, including reduced abdominal pain, better appetite, and improved daily functioning. But larger trials are needed before cannabis can be considered a reliable treatment for Crohn’s. For people already managing the condition with conventional therapies, it may serve as a complementary option rather than a replacement.
Sleep
Many people use cannabis primarily to fall asleep faster, and there’s some basis for this. THC has been shown to decrease sleep latency, meaning the time it takes to drift off after getting into bed. For people who lie awake for 30 or 45 minutes each night, this can feel like a significant quality-of-life improvement.
The trade-off involves what happens once you’re asleep. Regular cannabis users show measurably less REM sleep, the stage associated with dreaming, memory consolidation, and emotional processing. They also take longer to enter REM once they do fall asleep. In the short term, less REM sleep might not feel like a problem. Over months or years, reduced REM sleep has been linked to poorer memory and mood regulation. So cannabis may help you fall asleep while subtly degrading the quality of sleep you’re getting. For occasional use during a rough patch of insomnia, the trade-off may be worth it. For nightly use over long periods, the picture is less favorable.
What About Glaucoma?
This one persists as a popular belief, but the reality doesn’t hold up. Research from the 1970s and 1980s did show that cannabis lowers pressure inside the eye, which is the key risk factor for glaucoma. The problem is that the effect lasts only three to four hours. Glaucoma requires 24-hour pressure management, so you’d need to consume cannabis six to eight times a day, every day, at doses that would make driving, working, or doing much of anything impractical.
Other delivery methods haven’t solved the problem. Eye drops made from cannabis compounds caused burning and irritation without lowering pressure effectively. A compound placed under the tongue showed no pressure reduction at all. Perhaps most concerning, cannabis may reduce blood flow to the optic nerve, potentially canceling out whatever benefit comes from lower eye pressure. The American Academy of Ophthalmology does not recommend cannabis for glaucoma treatment.
Legal Status in the U.S.
Cannabis remains a controlled substance at the federal level, though its classification is actively changing. As of mid-2025, the Department of Justice and DEA have moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III, a less restrictive category than the Schedule I designation cannabis has held since 1970. A broader hearing on fully rescheduling all marijuana from Schedule I to Schedule III is set to begin June 29, 2026.
Schedule III classification puts cannabis in the same legal tier as drugs like testosterone and certain codeine formulations. This shift doesn’t legalize recreational use federally, but it has practical implications: it opens the door for more clinical research, potentially allows tax deductions for cannabis businesses, and signals a federal acknowledgment that cannabis has accepted medical uses. State laws still vary widely, with some permitting both medical and recreational use and others restricting or prohibiting it entirely.
Benefits vs. Limitations
The honest picture of cannabis benefits is that they’re real but specific. Pain relief, nausea control, appetite stimulation, and spasticity reduction have the strongest evidence, and for people dealing with those particular problems, cannabis can meaningfully improve daily life. The benefits tend to be most clear-cut when conventional treatments have already been tried and found lacking.
Where the evidence gets weaker is in the broader wellness claims: that cannabis reliably improves sleep quality, cures anxiety, or treats conditions like glaucoma. Some of these have a kernel of truth wrapped in significant limitations. The short duration of its effect on eye pressure, the suppression of REM sleep, and the small sample sizes in digestive disease trials all illustrate the gap between “shows promise” and “proven benefit.” For most medical uses, cannabis works best as one tool among several rather than a standalone solution.